Danaher Unit Cepheid Reportedly Urged to Cut Mpox Test Prices for Better Access

MT Newswires Live11-15 21:13

Danaher's (DHR) Cepheid subsidiary is being urged by global health groups to reduce the price of its GeneXpert mpox test to $5 from $20 to improve access in low-income nations, media outlets reported Friday.

The World Health Organization declared mpox a global public health emergency this summer as an outbreak in the Democratic Republic of Congo began spreading to neighboring countries, according to the reports.

GeneXpert is one of the three mpox tests approved for emergency use by the WHO. This test is crucial because machines that process the results are available across Africa, the reports said.

Danaher previously reduced its tuberculosis test prices to $7.97 last year following pressure from activists, Reuters said.

Cepheid did not immediately respond to MT Newswires' request for comment.

Price: 237.76, Change: -1.62, Percent Change: -0.68

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment